CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
25.02
-0.42 (-1.65%)
May 27, 2025, 2:06 PM - Market open
CG Oncology Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for CG Oncology stock ranges from a low of $41 to a high of $75. The average analyst price target of $64 forecasts a 155.80% increase in the stock price over the next year.
Price Target: $64.00 (+155.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 7 | 7 | 7 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $52 | Buy | Maintains | $55 → $52 | +107.83% | May 19, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $41 | Buy | Initiates | $41 | +63.87% | May 2, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $66 → $68 | Buy | Maintains | $66 → $68 | +171.78% | Apr 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $75 | Buy | Reiterates | $75 | +199.76% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +199.76% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
921.36K
from 1.14M
Decreased by -19.11%
Revenue Next Year
115.05M
from 921.36K
Increased by 12,387.03%
EPS This Year
-1.84
from -1.41
EPS Next Year
-1.71
from -1.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.1M | 241.5M | 347.8M | ||
| Avg | 921,356 | 115.1M | 238.0M | ||
| Low | n/a | 49.0M | 130.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 84.4% | 26,115.7% | 202.3% | ||
| Avg | -19.1% | 12,387.0% | 106.9% | ||
| Low | - | 5,218.2% | 13.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.05 | -0.11 | 0.87 |
| Avg | -1.84 | -1.71 | -0.40 |
| Low | -2.16 | -3.49 | -1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.